Background-Although a variety of prognostic tools have been shown to predict rehospitalization and mortality in heart failure patients, their utility in assessing future costs is less clear. We assessed whether health status assessment with the Kansas City Cardiomyopathy Questionnaire (KCCQ) predicts future costs in stable heart failure outpatients with left ventricular dysfunction after myocardial infarction.
Accordingly, we examined the relationship of KCCQ scores among heart failure outpatients and 1-year costs using the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), a randomized multicenter trial of aldosterone blockade in patients with acute myocardial infarction (MI) complicated by heart failure and left ventricular dysfunction. 15 Because of the detailed clinical and cost information collected, serial measurements of patients' health status, and close trial follow-up, 16 EPHE-SUS represents an excellent opportunity to address this current gap in knowledge.
Methods

Study Population
EPHESUS was an international, multicenter, randomized trial that evaluated the effect of the selective aldosterone blocker eplerenone on morbidity and mortality among patients with acute MI complicated by heart failure and left ventricular dysfunction between December 27, 1999, and December 31, 2001 . Its study design has been previously described. 15 Briefly, 6632 patients with confirmed MI, left ventricular ejection fraction Յ40%, and either clinical heart failure (as demonstrated by pulmonary rales, venous congestion on chest x-ray, or presence of a third heart sound) or diabetes mellitus were randomized to eplerenone or placebo and were subsequently followed up for a mean of 16 months.
For the purposes of this study, because we were interested primarily in predicting future healthcare costs among study participants with stabilized heart failure, we included only those patients from the 10 prespecified countries participating in the EPHESUS quality-of-life substudy who survived their index hospitalization to the 1-month baseline (nϭ2191). 16 The substudy involved serial evaluations of patient health status with the KCCQ, a self-administered 23-item instrument with established validity, reliability, and prognostic utility. 14 We excluded patients enrolled in EPHESUS with diabetes mellitus but no clinical heart failure (nϭ292) and those who did not complete a 1-month KCCQ (233 patients lost to follow-up before 1 month; 147 patients without a 1-month visit, and 3 patients with an incomplete KCCQ), so our final study population comprised 1516 patients.
Health Status Assessment
Patient health status assessment was performed at the 1-month visit with the KCCQ. The KCCQ evaluates distinct health status domains for heart failure (physical limitations, symptoms, social function, self-efficacy, and quality of life), and its value over non-disease-specific instruments has been previously demonstrated. 13, 14 An overall score based on contributions from each domain quantifies the multiple domains of the KCCQ into a single summary score. Scores from the KCCQ are transformed to a range from 0 to 100, with higher scores denoting better health status. Assessment with the KCCQ also was performed at the 3-month follow-up in 1358 patients (90% of those who completed the 1-month assessment).
Cost Assessment
The EPHESUS economic substudy, which prospectively evaluated direct costs incurred during the follow-up period using a predefined algorithm, has been previously described. 17 Briefly, costs from all participating countries were determined by quantifying resource use, applying the US Medicare Fee Schedule, and standardizing costs to US dollars for the year 2001. For inpatient hospitalizations during follow-up, an investigator blinded to patient characteristics and treatment group assigned diagnosis-related groups to each hospitalization. Costs were then estimated from average Medicare reimbursement rates obtained from the Medicare Part A file. 18 Outpatient procedures and services were similarly captured in a blinded fashion with trial case report forms. Procedural codes were used to determine Medicare reimbursement rates for procedures, and physician professional costs were estimated as a percentage share of the hospital costs according to the diagnosis-related group. 19 Finally, average wholesale prices were used to determine outpatient medication costs. 20 In addition, because mortality rates may differ by KCCQ score, we accounted for the societal cost of death (US $8000) derived from prior cost-effectiveness studies to ensure no bias from competing risks because patients who die earlier have less exposure time to incur subsequent costs. 18, 21, 22 
Independent Variable
The independent variable of interest was the KCCQ at 1 month after enrollment in EPHESUS. In a secondary analysis, the KCCQ at 3 months was used as the baseline to demonstrate reproducibility. Based on prior work, the KCCQ was evaluated categorically by prespecified cut points (0 to Ͻ25, 25 to Ͻ50, 50 to Ͻ75, and 75 to 100) and as a continuous variable. 11, 16, 23 Outcome Assessment
The main outcome was 1-year costs from the 1-month baseline assessment (ie, from month 1 to month 13 after randomization).
All-cause mortality rates during this 1-year period also were examined and accounted for in calculating costs, as described above. All mortality end points were adjudicated by a blinded critical events committee. 15 To examine the reproducibility of our findings, we repeated our analyses of 1-year costs from the 3-month assessment (from month 3 to month 15 after randomization).
Statistical Analysis
Baseline characteristics were compared across KCCQ categories through the use of Mantel-Haenszel trend tests for categorical variables and ANOVA linear trend tests for continuous variables. Kaplan-Meier survival curves were used to examine the unadjusted relationship between KCCQ categories and 1-year death from all causes. Sequential multivariable hierarchical regression models were then constructed to assess whether the prognostic impact of baseline KCCQ on future cost was independent of other patient characteristics. Because of the skewness of the cost data, generalized linear models were used, which allow for nonnormal distributions. Our models used a ␥ error distribution and log link for expected costs, which were found by residual plots to fit the data reasonably well. Because a log link was used, cost comparisons are expressed in relative rather than absolute differences.
All models included adjustment for treatment randomization group and country as fixed effects and study enrollment center as a random effect. The initial model included only KCCQ categories and study center. The second model added demographic characteristics (age, gender, and race), medical comorbidities (prior heart failure, MI, or atrial fibrillation; prior anginal symptoms; hypertension; dyslipidemia; diabetes mellitus; stroke; and chronic lung disease), , and medications at 1 month (aspirin, thienopyridines, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, ␤-blockers, diuretics, and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors). Continuous variables were assessed for nonlinearity and were transformed when appropriate through the use of restricted cubic splines. A third and final model included all the aforementioned covariates and adjusted further for New York Heart Association (NYHA) class to determine whether the prognostic utility of the KCCQ was independent of all clinical markers of heart failure severity. Least-squares mean estimates of cost by KCCQ groups were calculated, along with cost ratios and confidence intervals (CIs) versus the reference group of 75 to 100 and P values for linear trends across KCCQ groups. Collinearity diagnostics were computed to determine the stability of effect estimates in the regression models. We also assessed the KCCQ as a continuous variable, including the use of 5-knot restricted cubic splines to examine whether a "cutoff" existed at which the association of KCCQ costs was stronger (ie, if PϽ0.05 for test for nonlinearity).
Of the 1516 patients in the study cohort, 1141 (75%) were alive at the end of 1 year, 130 (9%) died, and 245 (16%) were censored before completion of the 1-year follow-up. Censoring was due almost entirely to early termination of the study (nϭ239), with only 6 patients censored because of lost follow-up. The meanϮSD time to follow-up among censored patients was 10Ϯ2 months and did not differ by KCCQ group (Pϭ0.15). To examine the effect of censoring on estimates of 1-year costs, we used the method of Zhao and Tian 24 and Zhao et al 25 that weights observations by the inverse probability of being censored and integrates over patients' cost histories to correct for censoring bias. This analysis revealed a negligible bias resulting from censoring (Ϫ$167) that also did not vary by KCCQ group (Pϭ0.98). Similar results were found for 1-year costs after the 3-month visit. Therefore, the results presented here are not corrected for censoring.
Data on at least one of the covariates were missing for 7% of patients (only 10 of the 32 covariates had any missing values; missing rates ranged from Ͻ0.1% to 3%). We used multiple imputation methods to impute missing values for these covariates on the basis of all other observed data. Imputations were performed with Markov Chain Monte Carlo methods as implemented in SAS PROC MI. Five imputed data sets were generated; analyses were replicated across data sets and pooled to obtain final estimates. The results using these imputed values were virtually identical to those obtained on patients with the complete data; the former are presented here.
To explicitly examine direct medical costs, we repeated the analyses without attributing costs for death. To demonstrate the reproducibility of our findings, models were replicated using KCCQ scores from the 3-month visit (instead of the 1-month visit) and 1-year costs from this visit (costs from 3 to 15 months after randomization).
For all analyses, the null hypothesis was evaluated at a 2-sided significance level of 0.05 with 95% CIs calculated. All analyses were conducted with SAS 9.1 (SAS Institute, Inc, Cary, NC) and R version 2.6.2. 26 The institutional review board or ethics committee at each site involved in the EPHESUS trial approved the protocol, and all patients provided written informed consent before enrollment.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Of the initial 1516 patients in the study cohort, 685 (45.2%) had good health status (KCCQ score, 75 to 100), 510 (33.6%) had fair health status (KCCQ score, 50 to Ͻ75), 262 (17.3%) had poor health status (KCCQ score, 25 to Ͻ50), and 59 (3.9%) had the worst health status (KCCQ, 0 to Ͻ25) 1 month after hospitalization. In general, medical therapy for the entire heart failure cohort and across all 4 KCCQ groups was excellent. Patients with lower health status were older and more likely to be female; more likely to have prior heart failure, MI, and angina, as well as coexisting diabetes, cerebrovascular disease, and chronic lung disease; and more likely to have higher Killip class, a lower left ventricular ejection fraction, and no revascularization procedures performed on initial presentation (Table 1) . At the 1-month follow-up, patients with lower heath status also had higher resting heart rates, lower diastolic blood pressures, lower serum sodium levels, and lower renal glomerular filtration rates; were more likely to have been hospitalized since discharge; were less likely to be taking aspirin and ␤-blockers; and were more likely to be using diuretic agents.
Kaplan-Meier survival curves showed that an inverse graded relationship existed between the KCCQ score and mortality from all causes (PϽ0.001) (Figure 1 ). In unadjusted analysis, patients with good health status (KCCQ Ն75) incurred the lowest 1-year costs (mean, $9628; median, $4190; interquartile range, $2659 to $10 623), whereas patients with the worst health status (KCCQ Ͻ25) incurred the highest costs (mean, $18 476; median, $10 383; interquartile range, $4371 to $25 760) ( Table 2 ). Greater healthcare resource use among those with worse health status was due largely to both higher rates of hospitalization and longer lengths of stay for heart failure and other cardiovascular causes (Table 3 ). This pattern of resource use across KCCQ categories remained proportionate throughout the 12 months of follow-up ( Figure 2 ).
After adjustment for country, enrollment site, and all clinical covariates except NYHA class, an inverse graded relationship was found between KCCQ scores and 1-year costs (PϽ0.0001) ( Table 4 ). Compared with patients with good health status (KCCQ of Ն75), patients with fair health status (KCCQ, 50 to 74) incurred incremental 1-year costs of $1520 (cost ratio, 1.23; 95% CI, 1.05 to 1.43). In contrast, patients with poor (KCCQ, 25 to 49) and the worst (KCCQ Ͻ25) health status incurred incremental 1-year costs of $4265 (cost ratio, 1.63; 95% CI, 1.34 to 1.99) and $8999 (cost ratio, 2.34; 95% CI, 1.62 to 3.38), respectively. Further adjustment for NYHA class led to only partial attenuation of the effect size, and the KCCQ remained a strong independent predictor of 1-year costs (Pϭ0.0002). In addition, these relationships remained essentially unchanged when we excluded costs for death in our analyses (Table 4 ). Table 5 lists significant predictors of 1-year costs (PϽ0.05) in the final fully adjusted model. Variance inflation factors (which measure the degree to which variances are inflated because of collinearity with other model variables) were 1.5 for KCCQ and between 1.1 and 2.0 for the other significant predictors, well below the threshold of 10 that is typically used to signal multicollinearity concerns. 27 When the KCCQ was examined as a continuous variable, in the full model adjusted for all covariates and NYHA class, each 5-point-lower baseline 1-month KCCQ score was associated with a 4.0% increase in 1-year costs (95% CI, 2.2% to 5.9%; PϽ0.0001). The association was linear on the log scale (Pϭ0.52 for nonlinearity by restricted cubic splines), indicating that the 4.0% rate was constant across the range of KCCQ scores without a discernible cut point at which the association between KCCQ and costs was attenuated. Finally, when we used the 3-month KCCQ as the baseline and followed up patients for 1-year costs from this visit, our findings were essentially unchanged (see Tables 2 through 4 ).
Discussion
Our findings demonstrate that patient health status assessments with the KCCQ can identify heart failure outpatients with left ventricular dysfunction after MI who are likely to have high resource use over the following year despite excellent medical therapy. We found a graded inverse relationship between health status and 1-year costs, with incremental annual costs among patients with the worst health status being nearly $9000 greater than those for patients with the best health status. The KCCQ remained predictive of costs even after adjustment for NHYA class, suggesting that health status, from a patient-centered perspective, carries significant incremental prognostic information. Moreover, we found that these associations between health status and 1-year costs were reproducible at a subsequent outpatient visit. Collectively, these findings suggest that the KCCQ can be used as an effective serial monitoring instrument to help identify post-MI heart failure patients with left ventricular dysfunction likely to have high resource use over the next year. Although the vast majority of prognostic tools in heart failure have focused on clinical end points such as mortality and rehospitalization, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] the ability of these tools to predict costs to society is less clear. Because of competing risks, it is important to demonstrate that a prediction tool has prognostic utility for both clinical outcomes and costs because it is plausible that patients with chronic diseases who are more likely to die may actually incur fewer costs than patients who remain alive. In the present study, we were able to demonstrate that patients with poorer health status incurred significantly higher costs, primarily because of a greater frequency and duration of inpatient hospitalization.
The ability to prognosticate cost in heart failure is of interest to clinicians and payers alike and would allow more appropriate targeting of interventions with established efficacy. Heart failure hospitalizations have increased nearly 3-fold in the past 2 decades, and it has been estimated that 55% of these admissions may be preventable. 28 -30 Intensive disease management programs in heart failure have been shown to improve use and to decrease morbidity and mortality. These programs remain vastly underused, however. The reasons for this underuse include the labor-intensive process of patient education, empowerment, and monitoring; the incremental cost to hospitals for implementing disease management programs that, although cost-effective, are not cost neutral; and the loss of future revenue to hospitals by successfully preventing readmissions. 31 By using a simple and inexpensive tool to identify heart failure patients likely to have high subsequent resource use, clinicians can focus limited disease management resources on the sickest patients who are the most likely to benefit. Such an application may also improve the cost-effectiveness of these programs by targeting those with the greatest risk for high costs. Because it can also be repeated at subsequent visits, the KCCQ would allow clinicians to make real-time decisions in the outpatient setting about which patients may benefit from intensified heart failure management.
Current national guidelines recommend that "an ongoing review of the patient's clinical status is critical to the appropriate selection and monitoring of treatments," 32 and the use of standardized instruments such as the KCCQ has been cited as a marker of high-quality care. 33 The KCCQ is simple to administer and score, is inexpensive and noninvasive, uses standardized questionnaires with minimal interobserver variability compared with conventional measures such as NYHA class, and provides insights into patient-centered domains such as self-efficacy, quality of life, and social limitations. 14 With its ability to predict both costs and outcomes and to be administered repeatedly, the KCCQ could allow close monitoring of heart failure patients with left ventricular dysfunction after MI in whom prognostically important health status changes can be feasibly and readily identified, interpreted, and acted on.
Our study should be interpreted in the context of several potential limitations. First, there remains the possibility of residual confounding despite adjustment for a wide variety of demographic, clinical, and patient factors. Second, EPHESUS enrolled patients with symptomatic heart failure and left ventricular dysfunction after acute MI. Whether the KCCQ has similar prognostic significance in heart failure patients with nonischemic origins or preserved left ventricular ejection fraction requires further investigation. Third, our cost analysis evaluated costs associated with inpatient and outpatient utilization, but we did not examine other indirect costs such as loss of productivity or costs associated with heart failure specialty clinics. However, omission of these costs would likely have biased our estimates of effect toward the null, and we may have underestimated the true societal cost difference between those with poor and those with good health status. Fourth, we could not determine what proportion of the cost difference was due to a lower threshold among physicians (eg, primary care physicians or emergency room physicians) to hospitalize patients with worse baseline health status. However, we believe that any threshold differences, should they exist, are likely to reflect the routine practice of medicine in clinical decision making. Fifth, our analyses BP indicates blood pressure. Health status assessment with the KCCQ was prognostic of 1-year costs, even after adjustment for NYHA class. did not include the cost of device therapy, which was not standard therapy for patients with heart failure and left ventricular dysfunction at the time that the EPHESUS study was conducted. Finally, although our findings suggest an association between those with the lowest KCCQ scores and those with higher costs, whether intensified disease management programs in these high-risk patients can reduce costs remains to be established.
Conclusions
Health status assessment predicts resource use in post-MI heart failure patients with left ventricular dysfunction. Serial assessments of patients' health status in clinical practice may help identify high-risk patients who may benefit from intensified disease management programs.
